Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive, worldwide license agreement that could generate more than $1.3 billion for the Boston artificial intelligence (AI)-based drug developer.